Sentence examples for progression to date from inspiring English sources

It is in our opinion that the myeloid origin of metastasis is the most probable explanation of tumor progression to date.

Despite the importance of tumor oxygenation status in both therapy and prediction of disease progression, to date, there has been no consensus as to the best method for the detection of hypoxia [ 4].

The results of the randomized clinical trials designed to delay or prevent type 1 diabetes progression to date have indicated that timing of intervention, dosing and frequency, age at diagnosis, baseline C-peptide level, and number and type of Ab are important factors that need further investigation when designing effective treatment interventions.

Progression-free survival (PFS) was defined as the time interval from the beginning of oxaliplatin- or irinotecan-based chemotherapy to the date of disease progression or, if the patient died without evidence of progression, to the date of death.

Their involvement in cancer onset and progression is to date well assessed [3], to such an extent that we can now classify microRNAs as "oncomiRs" (oncogenic microRNAs) or, conversely, tumor suppressor microRNAs [4].

Besides EMT, the mesenchymal to amoeboid transition (MAT) has been described during tumour progression but to date, little is known about its transcriptional control and involvement in stemness.

Elevated IOP is the main risk factor for glaucoma development and progression; thus, to date, IOP reduction is the only well-documented, successful glaucoma treatment [ 4].

Clinical predictors of radiographic progression identified to date include elevated C-reactive protein, tobacco smoking, and the presence of baseline syndesmophytes.

That's one way of looking at their progression to a second date.

The criteria recommended by the European Leukemia Net (ELN) 2010 were used for the definition of complete hematological response, AP and BP. 12 Progression-free survival (PFS) was calculated from the date of therapy initiation to the date of progression to AP/BP or to the date of death from any cause.

One evidence-based trial revealed that the continuation of single agent monthly paclitaxel for a period of 12 months significantly delays the time to subsequent disease progression, 8 but to date, there remains no evidence that this strategy (or any other maintenance approach) improves overall survival in epithelial ovarian cancer.